291774-17-9

Basic information

• Product Name: 1,4-dibutyl-2-[[2'-(N-tert-butylaminosulfonyl)(1,1'-biphenyl)-4-yl]methyl]-4-methylpyrazolidine-3,5-dione
• Synonyms: 1,4-dibutyl-2-[[2'-(N-tert-butylaminosulfonyl)(1,1'-biphenyl)-4-yl]methyl]-4-methylpyrazolidine-3,5-dione
• CAS NO: 291774-17-9
• Molecular Weight: 527.728
• Mol File: 291774-17-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,4-dibutyl-2-[[2'-(N-tert-butylaminosulfonyl)(1,1'-biphenyl)-4-yl]methyl]-4-methylpyrazolidine-3,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dibutyl-2-[[2'-(N-tert-butylaminosulfonyl)(1,1'-biphenyl)-4-yl]methyl]-4-methylpyrazolidine-3,5-dione(291774-17-9)
• EPA Substance Registry System: 1,4-dibutyl-2-[[2'-(N-tert-butylaminosulfonyl)(1,1'-biphenyl)-4-yl]methyl]-4-methylpyrazolidine-3,5-dione(291774-17-9)

Safety Data

• Hazardous Substances Data: 291774-17-9(Hazardous Substances Data)

Upstream product

• 138733-52-5 [[2'-[(t-Butylamino)sulfonyl]-1,1'-biphenyl-4-yl]methyl] bromide 
• 291774-00-0 1,4-dibutyl-4-methylpyrazolidine-3,5-dione 
• 133-08-4 diethyl butylmalonate 
• 55114-29-9 butylmethylpropanedioic acid diethyl ester 
• 291773-90-5 1-benzyl-4-butyl-4-methylpyrazolidine-3,5-dione 

Downstream Products

• 291774-22-6 4'-(2,4-dibutyl-4-methyl-3,5-dioxo-pyrazolidin-1-ylmethyl)-biphenyl-2-sulfonic acid amide 

Relevant articles and documents

Synthesis and pharmacological evaluation of new pyrazolidine-3,5-diones as AT1 angiotensin II receptor antagonists

On the basis of the structure of the non-peptide receptor antagonist irbesartan, a new series of AT1 ligands was designed. In these compounds the central imidazolone nucleus of irbesartan was replaced by a pyrazolidine-3,5-dione structure. The key intermediate N-alkylpyrazolidine-3,5-diones were synthesized according to a new and general method. The most active compounds possess a spirocyclopentane ring at position 4, a linear butyl chain at position 1, and the [2'(5-tetrazolyl)biphenyl-4- yl]methyl or [2'-(benzoylaminosulfonyl)biphenyl-4-yl]methyl group at position 2. Affinity toward the AT1 and AT2 receptors was assessed by the ability of the compounds to competitively displace [3H]AII from its specific binding sites. The most active compounds, 28 and 48, displayed high affinity for the AT1 receptor, good selectivity AT1 versus AT2, and potent in vitro antagonist activity.